EUVIMED · CrossrefJournal
Annals of Oncology
ISSN 0923-7534 · Elsevier BV
Latest articles
Eight-year outcomes of testosterone suppression plus enzalutamide or a nonsteroidal antiandrogen for metastatic hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304)
Atezolizumab with or without tiragolumab in unresectable esophageal squamous-cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study
SKYSCRAPER-03: a phase III study of tiragolumab plus atezolizumab versus durvalumab in locally advanced, unresectable, stage III NSCLC after platinum-based concurrent chemoradiation
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial
ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer
Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer
Five-year outcomes of perioperative pembrolizumab for early-stage non-small-cell lung cancer from the randomized KEYNOTE-671 study
Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: five-year results from the phase III KEYNOTE-564 study
Long-term benefit from immune checkpoint inhibition in squamous esophageal cancer
Safety and antitumor activity of the first-in-class EGFR–HER3 bispecific antibody–drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase Ib study
TIGIT at a crossroads: lessons from SKYSCRAPER-03 in unresectable stage III NSCLC
Adjuvant olaparib in germline BRCA carriers: new certainties and remaining open questions from the updated OlympiA results
SKYSCRAPER-07: falling short of the top
Retraction notice to “389P Monocyte reprogramming in high-grade serous ovarian cancer and chemotherapy impact: A single-cell RNA sequencing study”
Table of Contents
Editorial Board
Autologous T-cell antigen coupler targeting HER2 (TAC01-HER2) in advanced or metastatic solid tumors
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer
SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer
Next-generation sequencing consensus guidelines for sarcoma: progress, gaps, and the path forward
Thymic radiation is associated with worse outcomes in patients with NSCLC
A multimodal deep learning model for preoperative prediction of post-operative complications in gastric cancer
Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW
Efficacy of cryotherapy in preventing taxane-induced neuropathy: the CryoPac randomised controlled trial
Gastric and oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Post-operative ctDNA dynamics and eligibility for treat-on-molecular result (TOMR) ALTAIR trial in colorectal cancer: insights from CIRCULATE-Japan
Sofetabart mipitecan, an antibody–drug conjugate targeting folate receptor alpha, in high-grade ovarian cancer: results from the first-in-human phase I study
Final analysis of the Neotorch study: perioperative toripalimab in combination with chemotherapy for patients with stage Ⅱ/Ⅲ resectable non-small-cell lung cancer
Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase III DeLLphi-304 study
Volumes
2026 · 1,1832025 · 5,4172024 · 4,0812023 · 4,2972022 · 4,1692021 · 3,5592020 · 3,7712019 · 4,8272018 · 4,1002017 · 4,4342016 · 4,4432015 · 2,8282014 · 3,0172013 · 1,6382012 · 3,6772011 · 6822010 · 7522009 · 5872008 · 7882007 · 6592006 · 6912005 · 6102004 · 4962003 · 4402002 · 5282001 · 6822000 · 6611999 · 7921998 · 5881997 · 5641996 · 5671995 · 4261994 · 5201993 · 4181992 · 4631991 · 3441990 · 197
EUVIMED